The Therapeutic Role of d-Cycloserine in Schizophrenia

Advances in Pharmacology

Volumn 76, Issue , 2016, Pages 39-66

  Goff, D ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

D Cycloserine; Glutamate; Glycine; Pharmacology; Plasticity; Schizophrenia

Indexed keywords

CYCLOSERINE; DEXTRO SERINE; GLUTAMIC ACID; GLYCINE; GLYCINE RECEPTOR; GLYCINE RECEPTOR ANTAGONIST; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG TARGETING; HUMAN; MEMORY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NERVE CELL PLASTICITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; COGNITIVE THERAPY; DRUG EFFECTS; METABOLISM;

COGNITIVE THERAPY; CYCLOSERINE; HUMANS; MEMORY; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84960194412     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/bs.apha.2016.02.001     Document Type: Chapter

References (145)

1. Aberg K.A., McClay J.L., Nerella S., Clark S., Kumar G., Chen W., van den Oord E.J. Methylome-wide association study of schizophrenia: Identifying blood biomarker signatures of environmental insults. JAMA Psychiatry 2014, 71(3):255-264. 10.1001/jamapsychiatry.2013.3730.
2. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Cappiello A., Krystal J.H. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Archives of General Psychiatry 2000, 57:270-276.
3. Andersson E., Hedman E., Enander J., Radu Djurfeldt D., Ljotsson B., Cervenka S., Ruck C. d-Cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: A randomized clinical trial. JAMA Psychiatry 2015, 72(7):659-667. 10.1001/jamapsychiatry.2015.0546.
4. Balu D.T., Coyle J.T. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neuroscience and Biobehavioral Reviews 2012, 35(3):848-870. S0149-7634(10)00169-7 [pii].
5. Balu D.T., Coyle J.T. The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. Current Opinion in Pharmacology 2015, 20:109-115. 10.1016/j.coph.2014.12.004.
6. Beneyto M., Meador-Woodruff J.H. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008, 33(9):2175-2186. 1301604 [pii]. 10.1038/sj.npp.1301604.
7. Binshtok A.M., Fleidervish I.A., Sprengel R., Gutnick M.J. NMDA receptors in layer 4 spiny stellate cells of the mouse barrel cortex contain the NR2C subunit. Journal of Neuroscience 2006, 26(2):708-715. 26/2/708 [pii]. 10.1523/JNEUROSCI.4409-05.2006.
8. Bjerkenstedt L., Edman G., Hagenfeldt L., Sedvall G., Wiesel F.A. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. British Journal of Psychiatry 1985, 147:276-282.
9. Breese G.R., Knapp D.J., Moy S.S. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: Potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neuroscience & Biobehavioral Reviews 2002, 26(4):441-455.
10. Breier A., Adler C.M., Weisenfeld N., Su T.P., Elman I., Picken L., Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach. Synapse 1998, 29:142-147.
11. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Carpenter W.T. The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. The American Journal of Psychiatry 2007, 164(10):1593-1602.
12. Burgdorf J., Zhang X.L., Weiss C., Gross A., Boikess S.R., Kroes R.A., Moskal J.R. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience 2015, 308:202-211. 10.1016/j.neuroscience.2015.09.004.
13. Cain C.K., McCue M., Bello I., Creedon T., Tang D.I., Laska E., Goff D.C. d-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophrenia Research 2014, 153(1-3):177-183. 10.1016/j.schres.2014.01.016.
14. Cascella N.G., Macciardi F., Cavallini C., Smeraldi E. d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study. Journal of Neural Transmission. General Section 1994, 95:105-111.
15. Chatburn A., Lushington K., Kohler M.J. Complex associative memory processing and sleep: A systematic review and meta-analysis of behavioural evidence and underlying EEG mechanisms. Neuroscience & Biobehavioral Reviews 2014, 47:646-655. 10.1016/j.neubiorev.2014.10.018.
16. Chen B.S., Roche K.W. Growth factor-dependent trafficking of cerebellar NMDA receptors via protein kinase B/Akt phosphorylation of NR2C. Neuron 2009, 62(4):471-478. S0896-6273(09)00296-7 [pii]. 10.1016/j.neuron.2009.04.015.
17. Cohen S.M., Tsien R.W., Goff D.C., Halassa M.M. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophrenia Research 2015, 167(1-3):98-107. 10.1016/j.schres.2014.12.026.
18. Corvin A., Morris D.W. Genome-wide association studies: Findings at the major histocompatibility complex locus in psychosis. Biological Psychiatry 2014, 75(4):276-283. 10.1016/j.biopsych.2013.09.018.
19. Costa J., Khaled E., Sramek J., Bunney W., Potkin S.G. An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. Journal of Clinical Psychopharmacology 1990, 10:71-72.
20. Davis M., Ressler K., Rothbaum B.O., Richardson R. Effects of D-cycloserine on extinction: Translation from preclinical to clinical work. Biological Psychiatry 2006, 60(4):369-375.
21. Domino E.F., Luby E.D. Phencyclidine/schizophrenia: One view toward the past, the other to the future. Schizophrenia Bulletin 2012, 38(5):914-919. 10.1093/schbul/sbs011.
22. Donzis E.J., Thompson L.T. D-cycloserine enhances both intrinsic excitability of CA1 hippocampal neurons and expression of activity-regulated cytoskeletal (Arc) protein. Neuroscience Letters 2014, 571:50-54. 10.1016/j.neulet.2014.04.035.
23. Dravid S.M., Burger P.B., Prakash A., Geballe M.T., Yadav R., Le P., Traynelis S.F. Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. Journal of Neuroscience 2010, 30(7):2741-2754. 30/7/2741 [pii]. 10.1523/JNEUROSCI.5390-09.2010.
24. D'Souza D., Morrissey K., Abi-Saab D. IV Glycine and oral D-cycloserine: Effects on CSF amino acids, plasma hormones, cognition and behavior in healthy humans 1994.
25. Duncan E.J., Szilagyi S., Schwartz M.P., Bugarski-Kirola D., Kunzova A., Negi S., Rotrosen J.P. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophrenia Research 2004, 71(2-3):239-248.
26. Evins A., Amico E., Posever T., Toker R., Goff D. D-cycloserine augmentation of risperidone in the deficit syndrome of schizophrenia. Schizophrenia Research 2002, 56:19-23.
27. Evins A.E., Fitzgerald S.M., Wine L., Rosselli R., Goff D.C. Placebo-controlled trial of glycine added to clozapine in schizophrenia. The American Journal of Psychiatry 2000, 157(5):826-828. 10.1176/appi.ajp.157.5.826.
28. Feld G.B., Lange T., Gais S., Born J. Sleep-dependent declarative memory consolidation-Unaffected after blocking NMDA or AMPA receptors but enhanced by NMDA coagonist D-cycloserine. Neuropsychopharmacology 2013, 38(13):2688-2697. 10.1038/npp.2013.179.
29. Ferrarelli F., Sarasso S., Guller Y., Riedner B.A., Peterson M.J., Bellesi M., Tononi G. Reduced natural oscillatory frequency of frontal thalamocortical circuits in schizophrenia. Archives of General Psychiatry 2012, 69:766-774. 10.1001/archgenpsychiatry.2012.147.
30. Flood J., Morley J., Lanthorn T. Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. European Journal of Pharmacology 1992, 221:249-254.
31. Forsyth J.K., Bachman P., Mathalon D.H., Roach B.J., Asarnow R.F. Augmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brain. Proceedings of the National Academy of Sciences of the United States of America 2015, 112(50):15331-15336. 10.1073/pnas.1509262112.
32. Goff D.C. Bitopertin: The good news and bad news. JAMA Psychiatry 2014, 71(6):621-622. 10.1001/jamapsychiatry.2014.257.
33. Goff D.C., Cather C., Gottlieb J.D., Evins A.E., Walsh J., Raeke L., Green M.F. Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study. Schizophrenia Research 2008, 106(2-3):320-327. S0920-9964(08)00375-7 [pii]. 10.1016/j.schres.2008.08.012.
34. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. The American Journal of Psychiatry 2001, 158:1367-1377.
35. Goff D., Henderson D., Evins A., Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biological Psychiatry 1999, 45:512-514.
36. Goff D.C., Hennen J., Tsai G., Evins A.E., Yurgelun-Todd D., Renshaw P. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biological Psychiatry 2002, 51:493-497.
37. Goff D.C., Herz L., Posever T., Shih V., Tsai G., Henderson D.C., Schoenfeld D. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology 2005, 179(1):144-150.
38. Goff D.C., Keefe R., Citrome L., Davy K., Krystal J.H., Large C., Webster E.L. Lamotrigine as add-on therapy in schizophrenia: Results of 2 placebo-controlled trials. Journal of Clinical Psychopharmacology 2007, 27(6):582-589. 00004714-200712000-00005 [pii]. 10.1097/jcp.0b013e31815abf34.
39. Goff D., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D., Coyle J. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry 1999, 56:21-27.
40. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. The American Journal of Psychiatry 1995, 152:1213-1215.
41. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., Coyle J.T. D-cycloserine added to clozapine for patients with schizophrenia. The American Journal of Psychiatry 1996, 153:1628-1630.
42. Gottlieb J.D., Cather C., Shanahan M., Creedon T., Macklin E.A., Goff D.C. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophrenia Research 2011, 131:69-74.
43. Gupta S.C., Hillman B.G., Prakash A., Ugale R.R., Stairs D.J., Dravid S.M. Effect of D-cycloserine in conjunction with fear extinction training on extracellular signal-regulated kinase activation in the medial prefrontal cortex and amygdala in rat. European Journal of Neuroscience 2013, 37(11):1811-1822. 10.1111/ejn.12197.
44. Hall J., Trent S., Thomas K.L., O'Donovan M.C., Owen M.J. Genetic risk for schizophrenia: Convergence on synaptic pathways involved in plasticity. Biological Psychiatry 2015, 77(1):52-58. 10.1016/j.biopsych.2014.07.011.
45. Hardingham G.E. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochemical Society Transactions 2009, 37(Pt 6):1147-1160. 10.1042/bst0371147.
46. Harre E.M., Galic M.A., Mouihate A., Noorbakhsh F., Pittman Q.J. Neonatal inflammation produces selective behavioural deficits and alters N-methyl-D-aspartate receptor subunit mRNA in the adult rat brain. European Journal of Neuroscience 2008, 27(3):644-653. 10.1111/j.1460-9568.2008.06031.x.
47. Heresco-Levy U., Ermilov M., Shimoni J., Shapira B., Silipo G., Javitt D.C. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. The American Journal of Psychiatry 2002, 159:480-482.
48. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Ermilov M. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry 2005, 57(6):577-585.
49. Heresco-Levy U., Javitt D., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. British Journal of Psychiatry 1996, 169:610-617.
50. Heresco-Levy U., Javitt D., Ermilov M., Mordel C., Silipo G., Lichenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry 1999, 56:29-36.
51. Heresco-Levy U., Javitt D.C., Ermilov M., Silipo G., Shimoni J. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. International Journal of Neuropsychopharmacology 1998, 3:131-135.
52. Hillman B.G., Gupta S.C., Stairs D.J., Buonanno A., Dravid S.M. Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory. Neurobiology of Learning and Memory 2011, 95:404-414. S1074-7427(11)00009-8 [pii]. 10.1016/j.nlm.2011.01.008.
53. Holt D.J., Coombs G., Zeidan M.A., Goff D.C., Milad M.R. Failure of neural responses to safety cues in schizophrenia. Archives of General Psychiatry 2012, 69(9):893-903. 10.1001/archgenpsychiatry.2011.2310.
54. Hopkins S.C., Campbell U.C., Heffernan M.L., Spear K.L., Jeggo R.D., Spanswick D.C., Large T.H. Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo. Pharmacology Research & Perspectives 2013, 1(1):e00007. 10.1002/prp2.7.
55. Ishiwata S., Umino A., Balu D.T., Coyle J.T., Nishikawa T. Neuronal serine racemase regulates extracellular D-serine levels in the adult mouse hippocampus. Journal of Neural Transmission (Vienna) 2015, 122(8):1099-1103. 10.1007/s00702-015-1388-2.
56. Itil T., Keskiner A., Kiremitci N., Holden J.M.C. Effect of phencyclidine in chronic schizophrenics. Canadian Psychiatric Association Journal 1967, 12:209-212.
57. Javitt D.C., Duncan L., Balla A., Sershen H. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action. Molecular Psychiatry 2005, 10:275-287.
58. Javitt D.C., Silipo G., Cienfuegos A., Shelley A.-M., Bark N., Park M., Zukin S.R. Adjunctive high-dose glycine in the treatment of schizophrenia. International Journal of Neuropsychopharmacology 2001, 4:385-391.
59. Javitt D., Zukin S. Recent advances in the phencyclidine model of schizophrenia. The American Journal of Psychiatry 1991, 148:1301-1308.
60. Javitt D.C., Zylberman I., Zukin S.R., Heresco L.U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. The American Journal of Psychiatry 1994, 151(8):1234-1236.
61. Kalisch R., Holt B., Petrovic P., De Martino B., Kloppel S., Buchel C., Dolan R.J. The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans. Cerebral Cortex 2009, 19(1):187-196. 10.1093/cercor/bhn076.
62. Karavanova I., Vasudevan K., Cheng J., Buonanno A. Novel regional and developmental NMDA receptor expression patterns uncovered in NR2C subunit-beta-galactosidase knock-in mice. Molecular and Cellular Neuroscience 2007, 34(3):468-480. S1044-7431(06)00277-6 [pii]. 10.1016/j.mcn.2006.12.001.
63. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neuroscience Letters 1980, 20:379-382.
64. Kinon B.J., Millen B.A., Zhang L., McKinzie D.L. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionyl in schizophrenia. Biological Psychiatry 2015, 78(11):754-762. 10.1016/j.biopsych.2015.03.016.
65. Kranjac D., Koster K.M., Kahn M.S., Eimerbrink M.J., Womble B.M., Cooper B.G., Boehm G.W. Peripheral administration of D-cycloserine rescues memory consolidation following bacterial endotoxin exposure. Behavioural Brain Research 2013, 243:38-43. 10.1016/j.bbr.2012.12.053.
66. Krystal J.H., Abi-Saab W., Perry E., D'Souza D.C., Liu N., Gueorguieva R., Breier A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 2005, 179(1):303-309.
67. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 1994, 51:199-214.
68. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
69. Lane H.Y., Lin C.H., Green M.F., Hellemann G., Huang C.C., Chen P.W., Tsai G.E. Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013, 70(12):1267-1275. 10.1001/jamapsychiatry.2013.2159.
70. Langton J.M., Richardson R. D-cycloserine facilitates extinction the first time but not the second time: An examination of the role of NMDA across the course of repeated extinction sessions. Neuropsychopharmacology 2008, 33(13):3096-3102. npp200832 [pii]. 10.1038/npp.2008.32.
71. Lawlor B.A., Davis K.L. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease?. Biological Psychiatry 1992, 31:337-350.
72. Ledgerwood L., Richardson R., Cranney J. D-cycloserine facilitates extinction of learned fear: Effects on reacquisition and generalized extinction. Biological Psychiatry 2005, 57(8):841-847.
73. Lewis D.A. Neuroplasticity of excitatory and inhibitory cortical circuits in schizophrenia. Dialogues in Clinical Neuroscience 2009, 11(3):269-280.
74. Li M., Li X., Zhang X., Ren J., Jiang H., Wang Y., Cheng W. Effects of prenatal chronic mild stress exposure on hippocampal cell proliferation, expression of GSK-3alpha, beta and NR2B in adult offspring during fear extinction in rats. International Journal of Developmental Neuroscience 2014, 35:16-24. 10.1016/j.ijdevneu.2014.02.004.
75. Linderholm K.R., Skogh E., Olsson S.K., Dahl M.L., Holtze M., Engberg G., Erhardt S. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophrenia Bulletin 2012, 38(3):426-432. 10.1093/schbul/sbq086.
76. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences 2008, 31(5):234-242. S0166-2236(08)00089-1 [pii]. 10.1016/j.tins.2008.02.005.
77. Liu Y., Wong T.P., Aarts M., Rooyakkers A., Liu L., Lai T.W., Wang Y.T. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. Journal of Neuroscience 2007, 27(11):2846-2857. 27/11/2846 [pii]. 10.1523/JNEUROSCI.0116-07.2007.
78. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug-sernyl. A.M.A. Archives of Neurology and Psychiatry 1959, 81:363-369.
79. Macciardi F., Lucca A., Catalano M., Marino C., Zanardi R., Smeraldi E. Amino acid patterns in schizophrenia: Some new findings. Psychiatry Research 1989, 32:63-70.
80. Malhotra A., Adler C., Kennison S., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. Biological Psychiatry 1997, 42:664-668.
81. Malhotra A., Pinals D., Adler C., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
82. Manoach D.S., Thakkar K.N., Stroynowski E., Ely A., McKinley S.K., Wamsley E., Stickgold R. Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages. Journal of Psychiatric Research 2010, 44(2):112-120. S0022-3956(09)00147-2 [pii]. 10.1016/j.jpsychires.2009.06.011.
83. Mao S.C., Hsiao Y.H., Gean P.W. Extinction training in conjunction with a partial agonist of the glycine site on the NMDA receptor erases memory trace. Journal of Neuroscience 2006, 26(35):8892-8899. 10.1523/JNEUROSCI.0365-06.2006.
84. Mao S.C., Lin H.C., Gean P.W. Augmentation of fear extinction by D-cycloserine is blocked by proteasome inhibitors. Neuropsychopharmacology 2008, 33(13):3085-3095. 10.1038/npp.2008.30.
85. Martina M., Gorfinkel Y., Halman S., Lowe J.A., Periyalwar P., Schmidt C.J., Bergeron R. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. Journal of Physiology 2004, 557(Pt 2):489-500. 10.1113/jphysiol.2004.063321.
86. McAllister A.K. Major histocompatibility complex I in brain development and schizophrenia. Biological Psychiatry 2014, 75(4):262-268. 10.1016/j.biopsych.2013.10.003.
87. McCallum J., Kim J.H., Richardson R. Impaired extinction retention in adolescent rats: Effects of D-cycloserine. Neuropsychopharmacology 2010, 35(10):2134-2142. npp201092 [pii]. 10.1038/npp.2010.92.
88. Menniti F.S., Lindsley C.W., Conn P.J., Pandit J., Zagouras P., Volkmann R.A. Allosteric modulators for the treatment of schizophrenia: Targeting glutamatergic networks. Current Topics in Medicinal Chemistry 2013, 13(1):26-54.
89. Mohn A., Gainetdinov P., Caron M., Koller B. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
90. Monahan J., Handelmann G., Hood W., Cordi A. D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacology, Biochemistry, and Behavior 1989, 34:649-653.
91. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994, 12(3):529-540. 0896-6273(94)90210-0 [pii].
92. Nitsche M.A., Jaussi W., Liebetanz D., Lang N., Tergau F., Paulus W. Consolidation of human motor cortical neuroplasticity by D-cycloserine. Neuropsychopharmacology 2004, 29(8):1573-1578. 1300517 [pii]. 10.1038/sj.npp.1300517.
93. Norberg M.M., Krystal J.H., Tolin D.F. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 2008, 63(12):1118-1126. S0006-3223(08)00106-6 [pii]. 10.1016/j.biopsych.2008.01.012.
94. Onur O.A., Schlaepfer T.E., Kukolja J., Bauer A., Jeung H., Patin A., Hurlemann R. The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans. Biological Psychiatry 2010, 67(12):1205-1211. S0006-3223(10)00064-8 [pii]. 10.1016/j.biopsych.2010.01.022.
95. Ori R., Amos T., Bergman H., Soares-Weiser K., Ipser J.C., Stein D.J. Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders. Cochrane Database of Systemic Reviews 2015, 5:Cd007803. 10.1002/14651858.CD007803.pub2.
96. Otto M.W., Basden S.L., McHugh R.K., Kantak K.M., Deckersbach T., Cather C., Smits J.A. Effects of D-cycloserine administration on weekly nonemotional memory tasks in healthy participants. Psychotherapy and Psychosomatics 2009, 78(1):49-54. 10.1159/000172620.
97. Ozawa T., Kumeji M., Yamada K., Ichitani Y. D-cycloserine enhances spatial memory in spontaneous place recognition in rats. Neuroscience Letters 2012, 509(1):13-16. 10.1016/j.neulet.2011.12.031.
98. Parnas A.S., Weber M., Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiology of Learning and Memory 2005, 83(3):224-231.
99. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nature Medicine 2007, 13(9):1102-1107. nm1632 [pii]. 10.1038/nm1632.
100. Pattwell S.S., Duhoux S., Hartley C.A., Johnson D.C., Jing D., Elliott M.D., Lee F.S. Altered fear learning across development in both mouse and human. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(40):16318-16323. 10.1073/pnas.1206834109.
101. Perry T.L. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neuroscience Letters 1982, 28:81-85.
102. Quartermain D., Mower J., Rafferty M.F., Herting R.L., Lanthorn T.H. Acute but not chronic activation of the NMDA-coupled glycine receptor with d-cycloserine facilitates learning and retention. European Journal of Pharmacology 1994, 257:7-12.
103. Rao K.V., Eidus L., Evans C., Kailasam S., Radhakrishna S., Somasundaram P.R., Tripathy S.P. Deterioration of cycloserine in the tropics. Bulletin of the World Health Organization 1968, 39(5):781-789.
104. Rauner C., Kohr G. Triheteromeric NR1/NR2A/NR2B receptors constitute the major N-methyl-D-aspartate receptor population in adult hippocampal synapses. Journal of Biological Chemistry 2011, 286(9):7558-7566. 10.1074/jbc.M110.182600.
105. Ren J., Li X., Zhang X., Li M., Wang Y., Ma Y. The effects of intra-hippocampal microinfusion of D-cycloserine on fear extinction, and the expression of NMDA receptor subunit NR2B and neurogenesis in the hippocampus in rats. Progress in Neuropsychopharmacology and Biological Psychiatry 2013, 44:257-264. 10.1016/j.pnpbp.2013.02.017.
106. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., Davis M. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry 2004, 61(11):1136-1144.
107. Rodgers R.J., Harvest H., Hassall C., Kaddour L.A. D-cycloserine enhances memory consolidation in the plus-maze retest paradigm. Behavioral Neuroscience 2011, 125(1):106-116. 2011-02594-012 [pii]. 10.1037/a0022343.
108. Rosse R.B., Theut S.K., Banay S.M., Leighton M., Scarcella E., Cohen C.G., Deutsch S.I. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label, pilot study. Clinical Neuropharmacology 1989, 12(5):416-424.
109. Rutherford B.R., Pott E., Tandler J.M., Wall M.M., Roose S.P., Lieberman J.A. Placebo response in antipsychotic clinical trials: A meta-analysis. JAMA Psychiatry 2014, 71(12):1409-1421. 10.1001/jamapsychiatry.2014.1319.
110. Rutter A.R., Fradley R.L., Garrett E.M., Chapman K.L., Lawrence J.M., Rosahl T.W., Patel S. Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS. European Journal of Neuroscience 2007, 25(6):1757-1766. 10.1111/j.1460-9568.2007.05446.x.
111. Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511(7510):421-427. 10.1038/nature13595.
112. Scholl J., Gunthner J., Kolling N., Favaron E., Rushworth M.F., Harmer C.J., Reinecke A. A role beyond learning for NMDA receptors in reward-based decision-making-a pharmacological study using d-cycloserine. Neuropsychopharmacology 2014, 39(12):2900-2909. 10.1038/npp.2014.144.
113. Segnitz N., Ferbert T., Schmitt A., Gass P., Gebicke-Haerter P.J., Zink M. Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain. Psychopharmacology 2011, 217(1):127-142. 10.1007/s00213-011-2262-z.
114. Shipton O.A., Paulsen O. GluN2A and GluN2B subunit-containing NMDA receptors in hippocampal plasticity. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 2014, 369(1633):20130163. 10.1098/rstb.2013.0163.
115. Simeon J., Fink M., Itil T., Ponce D. d-Cycloserine therapy of psychosis by symptom provocation. Comprehensive Psychiatry 1970, 11:80-88.
116. Smits J.A., Rosenfield D., Otto M.W., Powers M.B., Hofmann S.G., Telch M.J., Tart C.D. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: Evidence from the treatment of height phobia. Biological Psychiatry 2013, 73(11):1054-1058. 10.1016/j.biopsych.2012.12.009.
117. Stauffer V.L., Millen B.A., Andersen S., Kinon B.J., Lagrandeur L., Lindenmayer J.P., Gomez J.C. Pomaglumetad methionyl: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophrenia Research 2013, 150(2-3):434-441. 10.1016/j.schres.2013.08.020.
118. Suryavanshi P.S., Ugale R.R., Yilmazer-Hanke D., Stairs D.J., Dravid S.M. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice. British Journal of Pharmacology 2014, 171(3):799-809. 10.1111/bph.12518.
119. Tanahashi S., Yamamura S., Nakagawa M., Motomura E., Okada M. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. British Journal of Pharmacology 2012, 165(5):1543-1555. 10.1111/j.1476-5381.2011.01638.x.
120. Tang Y.P., Shimizu E., Dube G.R., Rampon C., Kerchner G.A., Zhuo M., Tsien J.Z. Genetic enhancement of learning and memory in mice. Nature 1999, 401(6748):63-69. 10.1038/43432.
121. Thompson L.T., Moskal J.R., Disterhoft J.F. Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine. Nature 1992, 359:638-641.
122. Tiihonen J., Wahlbeck K., Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis. Schizophrenia Research 2009, 109(1-3):10-14. S0920-9964(09)00003-6 [pii]. 10.1016/j.schres.2009.01.002.
123. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., Coyle J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Archives of General Psychiatry 1995, 52:829-836.
124. Tsai G.E., Yang P., Chang Y.C., Chong M.Y. D-alanine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 2006, 59(3):230-234. 10.1016/j.biopsych.2005.06.032.
125. Tsai G., Yang P., Chung L.-C., Lange N., Coyle J. D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 1998, 44:1081-1089.
126. Tsai G., Yang P., Chung L.-C., Tsai I.-C., Tsai C.-W., Coyle J. D-serine added to clozapine for the treatment of schizophrenia. The American Journal of Psychiatry 1999, 156:1822-1825.
127. Tuominen H.J., Tiihonen J., Wahlbeck K. Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophrenia Research 2005, 72:225-234.
128. Umbricht D., Alberati D., Martin-Facklam M., Borroni E., Youssef E.A., Ostland M., Santarelli L. A randomized, double-blind, proof-of-concept study of the effect of bitopertin, a glycine reuptake 2 inhibitor, on negative symptoms of schizophrenia. JAMA Psychiatry 2014, 71(6):637-646.
129. van Berckel B.N.M., Evenblij C.N., van Loon B.J.A.M., Maas M.F., van der Geld M.A.M., Wynne H.J., Kahn R.S. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: A double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 1999, 21:203-210.
130. van Berckel B.N., Hijman R., van der Linden J.A., Westenberg H.G., van Ree J.M., Kahn R.S. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biological Psychiatry 1996, 40:1298-1300.
131. Voineskos D., Rogasch N.C., Rajji T.K., Fitzgerald P.B., Daskalakis Z.J. A review of evidence linking disrupted neural plasticity to schizophrenia. Canadian Journal of Psychiatry 2013, 58(2):86-92.
132. Waziri R. Glycine therapy of schizophrenia (letter). Biological Psychiatry 1988, 23:209-214.
133. Wechsler D. Wechsler memory scale 1997, Psychological Corporation, San Antonio, TX. 3rd ed.
134. Weiser M., Heresco-Levy U., Davidson M., Javitt D.C., Werbeloff N., Gershon A.A., Zimmerman Y. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. Journal of Clinical Psychiatry 2012, 73(6):e728-e734. 10.4088/JCP.11m07031.
135. Werner-Seidler A., Richardson R. Effects of D-cycloserine on extinction: Consequences of prior exposure to imipramine. Biological Psychiatry 2007, 62(10):1195-1197. 10.1016/j.biopsych.2007.04.010.
136. Woo T.U., Walsh J.P., Benes F.M. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Archives of General Psychiatry 2004, 61(7):649-657. 10.1001/archpsyc.61.7.649.
137. Xi D., Keeler B., Zhang W., Houle J.D., Gao W.J. NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: Application of laser microdissection technique. Journal of Neuroscience Methods 2009, 176(2):172-181. 10.1016/j.jneumeth.2008.09.013.
138. Xia M., Liu Y., Figueroa D.J., Chiu C.S., Wei N., Lawlor A.M., Connolly T.M. Characterization and localization of a human serine racemase. Brain Research. Molecular Brain Research 2004, 125(1-2):96-104. 10.1016/j.molbrainres.2004.03.007.
139. Yadav R., Gupta S.C., Hillman B.G., Bhatt J.M., Stairs D.J., Dravid S.M. Deletion of glutamate delta-1 receptor in mouse leads to aberrant emotional and social behaviors. PLoS One 2012, 7(3):e32969. 10.1371/journal.pone.0032969.
140. Yaka R., Biegon A., Grigoriadis N., Simeonidou C., Grigoriadis S., Alexandrovich A.G., Shohami E. D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB Journal 2007, 21(9):2033-2041. fj.06-7856com [pii]. 10.1096/fj.06-7856com.
141. Yu H., Wang Y., Pattwell S., Jing D., Liu T., Zhang Y., Chen Z.Y. Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. Journal of Neuroscience 2009, 29(13):4056-4064. 10.1523/JNEUROSCI.5539-08.2009.
142. Yurgelun-Todd D.A., Coyle J.T., Gruber S.A., Renshaw P.F., Silveri M.M., Amico E., Goff D.C. Functional magnetic resonance imaging studies of schizophrenic patients during word production: Effects of D-cycloserine. Psychiatry Research 2005, 138(1):23-31.
143. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Manji H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006, 63(8):856-864. 10.1001/archpsyc.63.8.856.
144. Zhang X.Y., Ji F., Wang N., Chen L.L., Tian T., Lu W. Glycine induces bidirectional modifications in N-methyl-D-aspartate receptor-mediated synaptic responses in hippocampal CA1 neurons. Journal of Biological Chemistry 2014, 289(45):31200-31211. 10.1074/jbc.M114.570630.
145. Zhang Y., Llinas R.R., Lisman J.E. Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting. Frontiers in Neural Circuits 2009, 3:20. 10.3389/neuro.04.020.2009.